Micromet
Advent contact Don Drakeman
Company CEO Christian Itin
Antibody-based cancer, inflammation and autoimmune disease drugs
Antibody-based cancer, inflammation and autoimmune disease drugs
Micromet, which was listed on NASDAQ (MITI), focuses on therapies for oncology patients. The lead product candidate blinatumomab (MT103) has demonstrated single-agent activity in both adult and paediatric patients with acute lymphoblastic leukaemia and is now a broad-based development program. MT110, the second BiTE antibody, is in development in patients with advanced solid tumours. The company has a pipeline of candidates.
Amgen to Acquire Micromet